15 Feb '11, 5am

[ST] S'pore-French tie-up discovers potential treatment for Chikungunya

Chikungunya is prevalent in Africa, South Asia, and South-east Asia and is transmitted by the Aedes mosquito, the same mosquito that spreads dengue fever. -- PHOTO: NEA THE Singapore Immunology Network (SIgN), an institute of the Agency of Science, Technology and Research (A*STAR), and Vivalis, a French biopharmaceutical company, have discovered two new fully human monoclonal antibodies which could battle Chikungunya, a disease that currently has no available vaccine or specific treatment. The international team of scientists, coordinated by Dr Lucile Warter of SIgN, has published their groundbreaking discovery in the Journal of Immunology. Chikungunya is prevalent in Africa, South Asia, and South-east Asia and is transmitted by the Aedes mosquito, the same mosquito that spreads dengue fever. In Singapore alone, over 1,000 Chikungunya cases were reported over the period 20...

Full article: http://www.straitstimes.com/BreakingNews/Singapore/Story/...

Tweets

A step closer to finding Chikungunya vaccine

A step closer to finding Chikungunya vaccine

channelnewsasia.com 15 Feb '11, 3am

SINGAPORE: Scientists from A*STAR's Singapore Immunology Network (SIgN), and French biopharmaceutical company, VIVALIS, ar...

Singapore 'tops in energy efficiency investment...

The report, by boutique investment firm ReEX Capital Asia, assessed investment potential in Singapore, Malaysia, Indonesia...